| Symbol | BLTE |
|---|---|
| Name | BELITE BIO, INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 5820 OBERLIN DRIVE,SUITE 101, SAN DIEGO, California, 92121, United States |
| Telephone | +1 858 246-6240 |
| Fax | — |
| — | |
| Website | https://www.belitebio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001889109 |
| Description | Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. Additional info from NASDAQ: |
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
Read moreBelite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
Read moreBelite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Read moreScholl Hendrik Peter 🔴 sold 10.0K shares of BELITE BIO, INC (BLTE) at $147.11 ($1.5M) Transaction Date: Jun 18, 2026 | Filing ID: 276615
Read moreScholl Hendrik Peter 🔴 sold 10.0K shares of BELITE BIO, INC (BLTE) at $145.02 ($1.4M) Transaction Date: Jun 16, 2026 | Filing ID: 273321
Read more📋 Dr. Hendrick P. Scholl (Affiliate) plans to sell 10K shares of Belite Bio, Inc. (at $144.24 each, total $1.4M) Filed: Jun 16, 2026 | ID: 000623
Read moreBelite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
Read moreBelite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
Read moreBelite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
Read moreNew Form SCHEDULE 13G/A - BELITE BIO, INC <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0001193125-26-223925 <b>Size:</b> 7 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06388083 | A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subject… | Phase2 | STGD1 | Active_Not_Recruiting | 2024-07-31 | 2028-02-01 | ClinicalTrials.gov |
| NCT05949593 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety … | Phase3 | Geographic Atrophy | Active_Not_Recruiting | 2023-07-27 | 2027-08-31 | ClinicalTrials.gov |
| NCT05667688 | Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Ag… | Phase1 | Healthy Volunteer | Completed | 2022-11-28 | 2023-01-18 | ClinicalTrials.gov |
| NCT05244304 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety … | Phase3 | Stargardt Disease 1 | Completed | 2022-03-28 | 2025-09-11 | ClinicalTrials.gov |
| NCT05266014 | This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Saf… | Phase1 | Stargardt Disease | Completed | 2021-03-12 | 2023-08-15 | ClinicalTrials.gov |
| NCT04005807 | Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults | Phase1 | Healthy Volunteers | Completed | 2019-07-19 | 2019-12-20 | ClinicalTrials.gov |
| NCT03735810 | Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single… | Phase1 | Healthy Volunteer | Completed | 2018-11-15 | 2019-09-16 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Stargardt Disease 1 | COMPLETED | NCT05244304 |
| Tinlarebant | Other | Phase PHASE3 | Stargardt Disease 1 | COMPLETED | NCT05244304 |
| Placebo | Other | Phase PHASE3 | Stargardt Disease 1 | COMPLETED | NCT05244304 |
| Tinlarebant | Other | Phase PHASE3 | Stargardt Disease 1 | COMPLETED | NCT05244304 |
| Placebos | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03735810 |
| LBS-008 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03735810 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04005807 |
| BPN-14967 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04005807 |
| Tinlarebant (LBS-008) | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05667688 |
| tinlarebant | Other | Phase PHASE1 | Stargardt Disease | COMPLETED | NCT05266014 |
| Placebo | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT05949593 |
| Tinlarebant | Other | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT05949593 |
| Placebo | Other | Phase PHASE2 | STGD1 | ACTIVE_NOT_RECRUITING | NCT06388083 |
| Tinlarebant | Other | Phase PHASE2 | STGD1 | ACTIVE_NOT_RECRUITING | NCT06388083 |
| Tinlarebant (LBS-008) | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05667688 |
| tinlarebant | DRUG | Phase PHASE1 | Stargardt Disease | COMPLETED | NCT05266014 |
| Tinlarebant | DRUG | Phase PHASE2 | STGD1 | ACTIVE_NOT_RECRUITING | NCT06388083 |
| Placebo | DRUG | Phase PHASE2 | STGD1 | ACTIVE_NOT_RECRUITING | NCT06388083 |
| BPN-14967 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04005807 |
| Placebos | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03735810 |
| LBS-008 | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03735810 |